entertainment -WSS

entertainment

author：comprehensive 2025-08-25 07:29:23 - browse：3254

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Abortion pill case raises question: who can sue the FDA?

focus

hotspot

WSS

Why the world’s most expensive drug might be worth the price

Flagship, Pfizer team up in deal worth up to $7 billion

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Flagship, Pfizer team up in deal worth up to $7 billion

Twill hunts for pharma partner to market its depression app

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

leisure time

entertainment

focus

Medicare proposal to cover medical devices draws a mixed reaction

States should stop sabotaging methadone treatment reform

How one medical school became remarkably diverse

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Tori Bowie and the unacceptable rates of Black maternal death

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD podcast: mifepristone case, GLP

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Patient advocates debate FDA's accelerated approval process

Wikipedia

Twill hunts for pharma partner to market its depression app

Flagship, Pfizer team up in deal worth up to $7 billion

A Theranos scientist

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

House passes resolution saying Israel isn't a 'racist or apartheid state'

Study: Hearing aids may slow cognitive decline in those at risk

leisure time

focus

hotspot

entertainment